NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
IPO Year: 2004
Exchange: NASDAQ
Website: nuvasive.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2023 | $57.72 | Overweight → Equal Weight | Wells Fargo |
| 2/10/2023 | $63.00 → $52.00 | Buy → Neutral | Citigroup |
| 2/10/2023 | $51.00 → $52.50 | Buy → Hold | Truist |
| 1/6/2023 | Buy → Hold | Needham | |
| 10/18/2022 | $53.00 | Overweight | Barclays |
| 10/12/2022 | $45.00 | Hold | Jefferies |
| 4/13/2022 | $60.00 → $65.00 | Buy | Truist |
| 3/28/2022 | $58.00 | Overweight | Wells Fargo |
| 1/7/2022 | $62.00 → $60.00 | Equal-Weight | Morgan Stanley |
| 12/21/2021 | $75.00 → $60.00 | Buy | Truist Securities |
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72
Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously
Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously
Needham downgraded NuVasive from Buy to Hold
Barclays initiated coverage of NuVasive with a rating of Overweight and set a new price target of $53.00
Jefferies initiated coverage of NuVasive with a rating of Hold and set a new price target of $45.00
Truist resumed coverage of NuVasive with a rating of Buy and set a new price target of $65.00 from $60.00 previously
Wells Fargo initiated coverage of NuVasive with a rating of Overweight and set a new price target of $58.00
Morgan Stanley reiterated coverage of NuVasive with a rating of Equal-Weight and set a new price target of $60.00 from $62.00 previously
Truist Securities reiterated coverage of NuVasive with a rating of Buy and set a new price target of $60.00 from $75.00 previously
–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi
SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle
–Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a
SAN DIEGO, May 4, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, May 10, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the first quarter of 2023. The dial-in numbers are 1-877-300-8521 for domestic callers a
– Full-year 2022 net sales grew 5.5% as reported, 8.5% on a constant currency basis – – Continued strong international growth in 2022 – – U.S. cervical delivers growth of greater than 20% year-over-year driven by C360 – – 2,000+ Pulse cases performed worldwide since commercial launch – SAN DIEGO, Feb. 22, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended December 31, 2022.
Capitalizes on complementary global commercial organizations and accelerates Globus Medical's and NuVasive's globalization strategies to increase customer reach and deepen surgeon relationships Brings together innovative technologies to create comprehensive procedural solutions offering to better support surgeons, healthcare providers and patients Leverages shared commitment to innovation to further both companies' efforts to address the full continuum of care and help solve unmet clinical needs Expands operational excellence capabilities to further serve and enable the combined commercial organizations to better support customers Strong financial profile and value creation opportunity Compa
SAN DIEGO, Jan. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its fourth quarter and full-year 2022 results on Wednesday, February 22, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, February 22, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the fourth quarter and full year ended December 31, 2022. The
– Net sales grew 9.0% as reported, 12.9% on a constant currency basis – – C360 portfolio delivers record quarter in cervical net sales – – Company updates full-year 2022 guidance – SAN DIEGO, Nov. 9, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2022. Third Quarter 2022 Net sales were $295.3 million, a 9.0% increase as reported and a 12.9% increase on a constant
SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close. NuVasive will hold a conference call on Wednesday, November 9, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the third quarter ended September 30, 2022. The dial-in numbers are 1-877-300-85
–Strong year-over-year net sales growth, driven by new product introductions– –Company reiterates full-year guidance range for reported year-over-year net sales growth of 6%–8%– –Company updates full-year guidance range for GAAP diluted EPS; maintains prior non-GAAP diluted EPS range provided May 4, 2022– SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2022.
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to
SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company
SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Amy Belt Raimundo to the Company's Board of Directors, effective August 9, 2021. Ms. Raimundo has more than 20 years of experience in healthcare, with extensive knowledge in medical technology, healthcare strategy, and digital health. Currently, she is the co-founder and Managing Partner for Convey Capital, a venture capital fund fo
SAN DIEGO, May 19, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Daniel J. Wolterman as independent chair of the NuVasive Board of Directors, effective immediately. Mr. Wolterman succeeds Gregory T. Lucier as the Company's Board chair, following Mr. Lucier's retirement from the Board on May 18, 2021. "As a long-standing member of our Board of Directors, Dan's expertise and leadership will help NuV
SAN DIEGO, May 10, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Juliet C. Cunningham as the vice president of Investor Relations, effective immediately. In this role, Ms. Cunningham is responsible for the Company's investor relations program and reports directly to Chief Financial Officer Matt Harbaugh. Ms. Cunningham has more than 25 years of experience in investor relations and corporate commu
SAN DIEGO, March 25, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced Gregory T. Lucier will be retiring from the NuVasive Board of Directors effective May 18, 2021. "I want to thank Greg for his leadership and guidance to NuVasive and the Board of Directors. His extensive medical device background and experience commercializing disruptive technology helped expand the Company's key growth areas and build a strong foundation for our long-term strategy," said J. Christopher Barry, chief executive officer of NuVasive. "Greg is a visio
SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Siddhartha Kadia, Ph.D. to the Company's Board of Directors, effective February 1, 2021. Dr. Kadia has more than 20 years of experience in the medical technology industry with expertise in globally commercializing disruptive technology. He most recently served as president and CEO of EAG Laboratories, a global scientific services company providing analytical testing and consulting solutions, which was acquired by Eurofins Scientific for $780 mi
15-12G - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
EFFECT - NUVASIVE INC (0001142596) (Filer)
S-8 POS - NUVASIVE INC (0001142596) (Filer)
S-8 POS - NUVASIVE INC (0001142596) (Filer)
S-8 POS - NUVASIVE INC (0001142596) (Filer)
SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle. "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi
NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond
–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi
SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle
–Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a
SAN DIEGO, May 4, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, May 10, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the first quarter of 2023. The dial-in numbers are 1-877-300-8521 for domestic callers a
AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive (NASDAQ:NUVA). As previously announced, under the terms of the merger agreement, Globus Medical will issue 0.75 of a share of Globus Medical Class A common stock in exchange for each share of NuVasive common stock owned at the closing of the transaction. "Globus Medical shareholders showed an overwhelming level of support for this merger,"
SAN DIEGO, April 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company's merger agreement with Globus Medical (NYSE:GMED). As previously announced, under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock owned at the closing of the transaction.
SAN DIEGO, April 17, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that proxy advisory firm, Glass Lewis & Co., LLC ("Glass Lewis"), recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (NYSE:GMED) at NuVasive's upcoming special meeting of shareholders ("the special meeting") scheduled for April 27, 2023. Only holders of record of NuVasive common stock as of the close of business on March 24, 2023, are entitled to vote at the special meeting.
SAN DIEGO, April 14, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (NYSE:GMED) at NuVasive's upcoming special meeting of shareholders ("the special meeting") scheduled for April 27, 2023. Only holders of record of NuVasive common stock as of the close of business on March 24, 2023 are entitled to vote at the special meetin
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SC 13G - NUVASIVE INC (0001142596) (Subject)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SC 13G - NUVASIVE INC (0001142596) (Subject)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SC 13G - NUVASIVE INC (0001142596) (Subject)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
Morgan Stanley analyst Jonathan Demchick maintains NuVasive (NASDAQ:NUVA) with a Equal-Weight and raises the price target from $40 to $45.
Over the past 3 months, 7 analysts have published their opinion on NuVasive (NASDAQ:NUVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 3 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 2 0 0 In the last 3 months, 7 analysts have offered 12-month price targets for NuVasive. The company has an average price target of $52.0 with a high of $58.00 and a low of $40.00. Below is a summary of how these 7 analysts rated NuVasive over the past 3 mon
Barclays analyst Matt Miksic maintains NuVasive (NASDAQ:NUVA) with a Overweight and raises the price target from $56 to $58.
NuVasive (NASDAQ:NUVA) reported quarterly earnings of $0.56 per share which met the analyst consensus estimate. This is a 19.15 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $317.80 million which missed the analyst consensus estimate of $323.59 million by 1.79 percent. This is a 2.37 percent increase over sales of $310.45 million the same period last year.
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimated to report quarterly earnings at $0.37 per share on revenue of $784.53 million. • Wallbox (NYSE:WBX) is likely to report earnings for its second quarter. • Seagen (NASDAQ:SGEN) is projected to report quarterly loss at $0.78 per share on revenue of $555.68 million. • Ardelyx (NASDAQ:ARDX) is likely to report quarterly loss at $0.12 per share on revenue of $15.88 million. • Blueprint Medicines (NASDAQ:BPMC) is expected to report quarterly loss at $2.58 per share on revenue of $45.00 million. • Colliers Intl Gr (NASDAQ:CIGI) is estimated to report quarterly earnings at $1.44 per share on r
NuVasive (NASDAQ:NUVA) is set to give its latest quarterly earnings report on Wednesday, 2023-08-02. Here's what investors need to know before the announcement. Analysts estimate that NuVasive will report an earnings per share (EPS) of $0.56. NuVasive bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.04, which was followed by a 0.1% increase in the share price
Truist Securities analyst Richard Newitter maintains NuVasive (NASDAQ:NUVA) with a Hold and raises the price target from $48 to $51.
Over the past 3 months, 5 analysts have published their opinion on NuVasive (NASDAQ:NUVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 3 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for NuVasive. The company has an average price target of $51.0 with a high of $58.00 and a low of $40.00. Below is a summary of how these 5 analysts rated NuVasive over the past 3 mon
Within the last quarter, NuVasive (NASDAQ:NUVA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 3 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 5 analyst offering 12-month price targets in the last 3 months, NuVasive has an average price target of $51.0 with a high of $58.00 and a low of $40.00. Below is a summary of how these 5 analysts rated NuVasive over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock Th